Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Multiple Myeloma
Related studies linked through entity extraction aliases.
A "Physician & Patient-powered" Cohort Registry (MY MYELOMA)
- Status
- RECRUITING
- Phase
- N/A
Geriatric-assessment Interventions to Address Functional Deficits in Older Adults w Multiple Myeloma
- Status
- COMPLETED
- Phase
- NA
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
- Status
- RECRUITING
- Phase
- PHASE2
Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide
- Status
- UNKNOWN
- Phase
- PHASE4
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Real Life Treatment for Multiple Myeloma (MM)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Stepping Up: A Trial of Activity Monitoring Devices in Patients Undergoing Autologous Stem Cell Transplant
- Status
- COMPLETED
- Phase
- NA
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
- Status
- COMPLETED
- Phase
- PHASE2
Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
- Status
- SUSPENDED
- Phase
- N/A
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM
- Status
- RECRUITING
- Phase
- PHASE2
REST - Replacing Steroids in the Transplant Ineligble
- Status
- COMPLETED
- Phase
- PHASE2
Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
MInimal Residual Disease Adapted Strategy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3